
Henri Stanton
Articles by Henri Stanton


At the 54th Annual Meeting of the American Society of Hematology, John Radford, MD, reported the results of the United Kingdom RAPID trial, in which PET-directed therapy provided an opportunity to avoid involved field radiotherapy, the current standard of care following abbreviated chemotherapy in early stage Hodgkin's lymphoma.

A unique targeted therapy, quizartinib, was able to clear leukemia cells from the bone marrow in more than 33% of patients with an aggressive form of acute myeloid leukemia marked by a mutation in the FLT3 gene.

Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.
Latest Updated Articles
- Extending Anticoagulation With Apixaban Reduces Recurrent VTE
Published: December 9th 2012 | Updated:
- Selective Inhibitor of FLT3 Allows High-Risk AML Patients to Bridge to Stem Cell Transplant
Published: December 10th 2012 | Updated:
- PET Can Identify Low-Risk Patients With Hodgkin's Lymphoma Who Need No Further Treatment Following Three Cycles of ABVD
Published: December 11th 2012 | Updated:
- ASH Conference Coverage
Published: February 26th 2013 | Updated: